NO20083639L - Aurorakinasemodulatorer og fremgangsmate for anvendelse - Google Patents

Aurorakinasemodulatorer og fremgangsmate for anvendelse

Info

Publication number
NO20083639L
NO20083639L NO20083639A NO20083639A NO20083639L NO 20083639 L NO20083639 L NO 20083639L NO 20083639 A NO20083639 A NO 20083639A NO 20083639 A NO20083639 A NO 20083639A NO 20083639 L NO20083639 L NO 20083639L
Authority
NO
Norway
Prior art keywords
compounds
disease states
affecting
modulating
aurora kinase
Prior art date
Application number
NO20083639A
Other languages
English (en)
Inventor
Vinod F Patel
Victor J Cee
Holly L Deak
Bingfan Du
Stephanie D Geuns-Meyer
Brian L Hodous
Hanh Nho Nguyen
Philip R Olivieri
Karina Romero
Laurie Schenkel
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/655,642 external-priority patent/US7560551B2/en
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO20083639L publication Critical patent/NO20083639L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)

Abstract

Den foreliggende oppfmnelse vedrører kjemiske forbindelser som har en generell formel (I), hvor A1, A2, C1, C2, D L1, L2, Z og R1-8 er definert her, og syntetiske mellomprodukter, som er i stand til å modulere forskjellige proteinkinasereseptorenzymer og derved påvirke forskjellige sykdomstilstander og tilstander relatert til aktivitetene av slike kinaser. For eksempel er forbindelsene i stand til å modulere Aurora-kinase og derved påvirke cellesyklusprosessen og celleproliferasjonen, for å behandle kreft og kreftrelaterte sykdommer. Oppfinnelsen omfatter også farmasøytiske preparater som inkluderer forbindelsene, og fremgangmåter for behandling av sykdomstilstander relatert til aktiviteten av Aurora-kinase.
NO20083639A 2006-01-23 2008-08-22 Aurorakinasemodulatorer og fremgangsmate for anvendelse NO20083639L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76167506P 2006-01-23 2006-01-23
US11/655,642 US7560551B2 (en) 2006-01-23 2007-01-18 Aurora kinase modulators and method of use
PCT/US2007/001714 WO2007087276A1 (en) 2006-01-23 2007-01-22 Aurora kinase modulators and method of use

Publications (1)

Publication Number Publication Date
NO20083639L true NO20083639L (no) 2008-10-22

Family

ID=40849087

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083639A NO20083639L (no) 2006-01-23 2008-08-22 Aurorakinasemodulatorer og fremgangsmate for anvendelse

Country Status (21)

Country Link
EP (1) EP1984353B1 (no)
JP (2) JP5280862B2 (no)
KR (2) KR101332975B1 (no)
AU (2) AU2007208351C1 (no)
BR (1) BRPI0706684A2 (no)
CA (1) CA2637658C (no)
CR (1) CR10213A (no)
DK (1) DK1984353T3 (no)
EA (1) EA018128B1 (no)
ES (1) ES2502790T3 (no)
GE (1) GEP20125643B (no)
HK (1) HK1167140A1 (no)
HR (1) HRP20160039T1 (no)
HU (1) HUE028504T2 (no)
IL (1) IL192812A (no)
MA (1) MA30224B1 (no)
MY (1) MY161884A (no)
NO (1) NO20083639L (no)
NZ (1) NZ569815A (no)
TN (1) TNSN08310A1 (no)
WO (1) WO2007087276A1 (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2637658C (en) * 2006-01-23 2012-07-17 Amgen Inc. Aurora kinase modulators and method of use
CA2682504C (en) * 2007-04-05 2012-10-30 Amgen Inc. Aurora kinase modulators and method of use
US8404694B2 (en) 2008-03-20 2013-03-26 Amgen Inc. Aurora kinase modulators and method of use
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
ES2433469T3 (es) * 2008-08-04 2013-12-11 Amgen Inc. Moduladores de la aurora cinasa y métodos de uso
US9126935B2 (en) 2008-08-14 2015-09-08 Amgen Inc. Aurora kinase modulators and methods of use
ES2397934T3 (es) 2008-12-17 2013-03-12 Amgen Inc. Compuestos de aminopiridina y carboxipiridina como inhibidores de fosfodiesterasa 10
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
ES2444777T3 (es) 2009-06-12 2014-02-26 Bristol-Myers Squibb Company Compuestos de nicotinamida útiles como moduladores de quinasas
HUE024568T2 (hu) 2009-09-11 2016-02-29 Amgen Inc N-(4-((3-(2-amino-4-pirimidinil)-2-piridinil)oxi)fenil)-4-(4-metil-2-tienil)-1-ftalazinamin antimitotikus szerre rezisztens rák kezelésében történõ alkalmazásra
WO2012129344A1 (en) 2011-03-23 2012-09-27 Amgen Inc. Fused tricyclic dual inhibitors of cdk 4/6 and flt3
WO2015084649A1 (en) * 2013-12-03 2015-06-11 Amgen Inc. Crystalline forms of n-(4-((3-(2-amino-4-pyrimidinyl) - 2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1 -phthalazinamine pharmaceutically acceptable salts and uses thereof
CA2988147C (en) 2015-06-03 2023-06-13 Bristol-Myers Squibb Company 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders
EP3351533A4 (en) 2015-09-18 2019-03-06 Kaken Pharmaceutical Co., Ltd. BIARY DERIVATIVE AND MEDICAMENT THEREOF
JP7032903B2 (ja) * 2016-10-12 2022-03-09 田辺三菱製薬株式会社 スルホンアミド化合物の製造方法
CN109384782A (zh) * 2017-08-04 2019-02-26 厦门大学 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
CN111302948A (zh) * 2020-04-13 2020-06-19 长兴进源新材料科技有限公司 一种2,2-双(4-氨基苯基)六氟丙烷合成方法
WO2024167848A1 (en) * 2023-02-06 2024-08-15 Type6 Therapeutics, Inc. Compounds, compositions, and methods of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2306671T3 (es) * 1999-10-07 2008-11-16 Amgen Inc. Inhibidores de triazina quinasa.
PL360439A1 (en) 2000-06-28 2004-09-06 Astrazeneca Ab Substituted quinazoline derivatives and their use as inhibitors
US6864255B2 (en) * 2001-04-11 2005-03-08 Amgen Inc. Substituted triazinyl amide derivatives and methods of use
ATE446093T1 (de) 2001-12-24 2009-11-15 Astrazeneca Ab Substituierte chinazolin-derivate als aurora- kinase inhibitoren
MXPA04007191A (es) * 2002-01-23 2005-03-31 Bayer Pharmaceuticals Corp Derivados de pirimidina como inhibidores de rho-quinasa.
EP1517904A4 (en) 2002-05-23 2007-02-21 Merck & Co Inc INHIBITORS OF MITOTIC KINESIN
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
GB0219054D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
US7262200B2 (en) 2002-10-25 2007-08-28 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
FR2853378B1 (fr) 2003-04-02 2006-03-10 Carbone Lorraine Composants Plaquettes de frein a disque ventilees
JP4707560B2 (ja) * 2003-12-29 2011-06-22 Ｍｓｄ株式会社 新規２−ヘテロアリール置換ベンズイミダゾール誘導体
AU2005245386B2 (en) * 2004-05-07 2008-11-27 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
CA2637658C (en) * 2006-01-23 2012-07-17 Amgen Inc. Aurora kinase modulators and method of use

Also Published As

Publication number Publication date
AU2010241280A1 (en) 2010-11-25
KR101300424B1 (ko) 2013-08-26
TNSN08310A1 (en) 2009-12-29
JP5280862B2 (ja) 2013-09-04
KR20080095889A (ko) 2008-10-29
NZ569815A (en) 2011-11-25
AU2007208351A1 (en) 2007-08-02
CA2637658A1 (en) 2007-08-02
EA200801732A1 (ru) 2009-02-27
DK1984353T3 (en) 2016-03-14
BRPI0706684A2 (pt) 2011-04-05
ES2502790T3 (es) 2014-10-06
EP1984353B1 (en) 2015-12-30
IL192812A0 (en) 2009-02-11
EA018128B1 (ru) 2013-05-30
JP2009528268A (ja) 2009-08-06
AU2007208351C1 (en) 2011-07-07
IL192812A (en) 2014-06-30
AU2007208351B2 (en) 2010-08-05
JP5753546B2 (ja) 2015-07-22
JP2013136585A (ja) 2013-07-11
HRP20160039T1 (hr) 2016-02-12
EP1984353A1 (en) 2008-10-29
KR101332975B1 (ko) 2013-11-25
AU2010241280B2 (en) 2013-02-28
KR20110133056A (ko) 2011-12-09
MY161884A (en) 2017-05-15
WO2007087276A1 (en) 2007-08-02
HUE028504T2 (en) 2016-12-28
GEP20125643B (en) 2012-09-25
CA2637658C (en) 2012-07-17
CR10213A (es) 2008-10-03
MA30224B1 (fr) 2009-02-02
HK1167140A1 (en) 2012-11-23

Similar Documents

Publication Publication Date Title
NO20083639L (no) Aurorakinasemodulatorer og fremgangsmate for anvendelse
MX2009010517A (es) Moduladores de cinasa aurora y metodos de uso.
ATE478861T1 (de) Multizyklische verbindung und verwendungsverfahren
MX2010010151A (es) Moduladores de cinasa aurora y metodo de uso.
MXPA06012613A (es) Derivados heterociclicos nitrogenados como moduladores de proteina cinasa y uso para el tratamiento de angiogenesis y cancer.
MX2021007157A (es) Heteroarilamidas utiles como inhibidores de kif18a.
MX2021007158A (es) Heteroarilamidas utiles como inhibidores de kif18a.
EA200900779A1 (ru) Производные дигидропиридина, полезные как ингибиторы протеинкиназы
NO20070907L (no) Pyrrolo-pyridin kinase modulatorer
EA200970402A1 (ru) Триазолопиридазиновые модуляторы протеинкиназ
MX2022001181A (es) Inhibidores de kif18a.
NO20073665L (no) 2-fenoksy-N-(1,3,4-tiadizol-2-yl) Pyridin-3-aminderivater og beslektede forbindelser som P2Y1 reseptor inhibitorer for behandling av tromboemboliforstyrrelser
NO20084712L (no) Nye farmasoytiske forbindelser
NO20083013L (no) Triazolopyridaziner som tyrosinkinasemodulatorer
NO20070199L (no) Substituerte kinazoloner som anti-kreftmidler
NO20075749L (no) 1H-Quinazoline-2,4-diones and their use as ampa-receptor ligands
NO20061194L (no) Mitotiske kinesininbibitorer
NO20061743L (no) Kinazolinderivater
EA200971077A1 (ru) Гетероциклические модуляторы киназы
NO20090581L (no) Hydroksylerte og metoksylerte syklopenta[D]pyrimidiner som AKT-proteinkinaseinhibitorer
NO20073859L (no) Pyrrolopyrazoler, potente kinaseinhibitorer
NO20080168L (no) Aminoquinolin- og aminoquinoazolinkinasemodulatorer
NO20081454L (no) Met-kinaseinhibitorer
NO20062884L (no) AKT-proteinkinaseinhibitorer
NO20076059L (no) 2,4-Diamino-pyrimidiner anvendt som aurorainhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application